资讯

The Pharma Letter13 小时
FDA misses decision deadline on Stealth’s Barth syndrome drug
US biotech firm Stealth BioTherapeutics (OTCQB: MITO) is facing renewed uncertainty after the American medicines regulator ...
Fierce Biotech16 小时
UPDATE: FDA misses PDUFA date for Stealth’s ultra-rare disease candidate, delaying ...
An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...